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TECHNICAL NOTE
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Abstract 
Background: Functional 3D organ models such as precision-cut lung slices (PCLS) have recently captured the 
attention of biomedical research. To enable wider implementation in research and development, these new biologi-
cally relevant organ models are being constantly refined. A very important issue is to improve the preparation of 
high-quality RNA (ribonucleic acid) from PCLS for drug discovery and development of new therapies. Gene expres-
sion analysis at different levels is used as an important experimental readout. Genome-wide analysis using microar-
rays is mostly applied for biomarker selection in disease models or in comprehensive toxicological studies. Specific 
biomarker testing by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) is often used in efficacy 
studies. Both applications require high-quality RNA as starting material for the generation of reliable data. Additionally, 
a small number of slices should be sufficient for satisfactory RNA isolation to allow as many experimental conditions 
as possible to be covered with a given tissue sample. Unfortunately, the vast amount of agarose in PCLS impedes RNA 
extraction according to the standard procedures.
Results: We established an optimized protocol for RNA isolation from PCLS from humans, rats, mice, marmosets, and 
rhesus macaques based on the separation of lysis and precipitation steps and a magnetic-bead cleanup procedure. 
The resulting RNA is of high purity and possesses a high degree of integrity. There are no contaminations affecting 
RTqPCR efficiency or any enzymatic step in sample preparation for microarray analysis.
Conclusions: In summary, we isolated RNA from PCLS from different species that is well suited for RTqPCR and for 
microarray analysis as downstream applications.
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Background
Functional 3D organ models are considered to have 
high impact and value in translational science. In lung 
research, tissue models such as precision-cut lung 
slices (PCLS), parenchymal strips, and isolated vessels 
and bronchi are used intensively and have been shown 
to be of importance, since their cellular composition 
includes varying cell types with many functions. PCLS, 
for example, contain epithelial cells, fibroblasts, smooth 
muscle cells, nerve fibers, and immune cells such as 
antigen-presenting cells, macrophages, and T-cells. Cells 
interact with each other, thereby reflecting the highly 
specialized function of the lung.
Precision-cut lung slices are used primarily for basic 
research and non-clinical efficacy and toxicity testing 
of (biological) compounds. The general perception has 
changed for many reasons. First of all, there have been 
significant improvements in the preparation and cul-
ture of ex vivo tissues, so that thin and precise sections 
are obtained, which can be maintained for days, weeks, 
and even months [1–3]. Today they form the basis for 
high quality research for drug discovery and new ther-
apy development. In the context of efficacy and toxicity 
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testing, they address the fact that individual cell types 
may respond quite differently to the same drug or sub-
stance. Therefore, lung tissue is exposed ex  vivo for 
example to drugs, chemicals, mitogens, and bronchoc-
onstricting agents, and is then analyzed for phenotyp-
ing of cellular changes, respiratory toxicity and efficacy, 
broncho- and vasoconstriction and dilation, immune 
responses, and tumor invasion [4–6]. Moreover, the 
use of human tissue is considered to be more predictive 
for human responses to pharmaceuticals than animal 
experiments. The high failure rate of drugs during clini-
cal trials is driving the pharmaceutical industry towards 
translational approaches—enabling early decisions in 
drug development based on models, for example with 
human cells and tissues. To enable wider implementa-
tion in research and development, new models will be 
developed and existing models will be further improved. 
Thus, constant work is being done to refine methodolo-
gies, endpoints, and analyses. A very important issue is to 
improve the preparation of high-quality RNA from PCLS 
for drug discovery and development of new therapies. 
This will open up the opportunity to analyze gene expres-
sion signatures, to run microarray analyses for pattern 
comparison, and to get mechanistic insights into selected 
targets and pathways in PCLS. Preparation of high-qual-
ity RNA from PCLS from different species, however, is 
still a difficult issue for many researchers working with 
agarose-filled lung tissue. The large amount of agarose in 
PCLS impedes RNA extraction according to the standard 
procedures.
High-quality RNA, however, is an essential require-
ment for convincing results to be obtained in gene 
expression analysis using RTqPCR [7–9] or microarrays 
[10]. Total RNA must fulfill the following main criteria: 
(a) free from protein, (b) undegraded, and (c) free from 
enzymatic inhibitors for downstream applications [11, 
12]. Therefore, RNA quality assessment includes both 
purity and integrity. The RNA fraction of interest for gene 
expression analysis is mRNA, which constitutes only a 
small amount (2–5%) of total RNA. The vast majority is 
rRNA (~80%) and it is this fraction that is generally used 
for quality evaluation when performing RNA extrac-
tions [13]. RNA has its absorption maximum at 260 nm 
and the ratio of absorbance at 260 and 280  nm is used 
to assess the purity of RNA preparation. Pure RNA has 
an A260/A280 ratio close to 2.0. An A260/A280 ratio greater 
than 1.8 is usually considered an acceptable indicator of 
good RNA quality, whereas lower levels indicate protein 
contamination [14]. Concerning RNA integrity highly 
accurate information is provided by the Bioanalyzer 2100 
(Agilent) as state-of-the-art technology. It is a microflu-
idic capillary system using a lab-on-a-chip approach, 
combining capillary electrophoresis with laser-induced 
fluorescent detection [7, 13, 15, 16]. The system employs 
an algorithm that interrogates the mobility of all fractions 
of RNA to estimate an RNA integrity number (RIN) as 
quality score [13, 15, 16]. The RIN software algorithm 
allows the classification of total RNA based on a rating 
system from 1 to 10, with 1 being the most degraded and 
10 being the most intact RNA [15, 16]. A RIN higher than 
five is recommended as good total RNA quality, a RIN 
higher than eight as perfect for downstream applications 
[7, 17]. The presence of potential contaminants that may 
act as enzymatic inhibitors in downstream applications 
can be determined by measuring the A260/A230 ratio. For 
pure RNA, values are around 2.0 can be expected. If the 
ratio is appreciably lower, it may indicate the presence of 
contaminants with absorbance at 230 nm, such as guani-
dinium isothiocyanate or phenol [13, 18, 19]. There is, 
however, no consensus on an acceptable lower limit of 
this ratio and it is presumed that the A260/A230 ratio addi-
tionally depends on RNA concentrations [18–20].
Our goal was to establish a protocol for RNA isolation 
from PCLS from different species that would yield RNA 
of high purity and integrity—even in the presence of a 
large amount of agarose in PCLS, which impedes RNA 
extraction—and is well suited for gene expression anal-
ysis as a downstream application. For validation, A260/
A280 ratios, RIN numbers, A260/A230 ratios, and impact 




Female rats [Wistar, Crl:WI (Wu), nulliparous and 
non-pregnant] and Balb/c mice [nulliparous and non-
pregnant] were housed under conventional and certi-
fied laboratory conditions in a regular 12-h dark/light 
cycle at an ambient temperature of 22 ± 2 °C and a rela-
tive air humidity of 55 ±  15%. Diet and drinking water 
were available ad libitum. Animals were acclimated for at 
least 1 week and sacrificed by an i.p. overdose (~100 mg/
kg body weight) of pentobarbital sodium (Narcoren®, 
Merial GmbH, Hallbergmoos, Germany) at the age of 
10–12 weeks.
Lungs of common marmosets (Callithrix jacchus) 
and rhesus macaques (Macaca mulatta) were obtained 
from German Primate Center (Göttingen, Germany). 
Marmosets were anesthetized using diazepam (Ratiop-
harm, Ulm, Germany) and alfaxalone (Alphaxan®, Jurox 
(UK) Limited, Worcestershire, United Kindom) followed 
by a lethal dose of pentobarbital sodium (Narcoren®, 
Merial GmbH, Hallbergmoos, Germany) under deep 
general anesthesia. Rhesus macaques (Macaca mulatta) 
were deeply anesthetized using a combination of keta-
mine (Ketavet®, Pfizer, New York, USA) and xylazine 
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(Rompun®, Bayer, Leverkusen, Germany). The abdominal 
cavity was opened along the linea alba, and the abdomi-
nal aorta was cannulated for blood sampling. The aortic 
cannula was subsequently used to administer a lethal 
dose of pentobarbital sodium (Narcoren®, Merial GmbH, 
Hallbergmoos, Germany).
Human lung tissue
Human lung lobes were obtained from male and female 
patients who underwent lung resection for cancer. Tumor 
free tissue was processed immediately on the day of 
resection as described below. The average age of patients 
was 60 ± 10 years, and 80% of them were smokers.
PCLS preparation, cultivation, and storage
Mouse lungs were filled in  situ. Rat, human, and non-
human primate lungs were filled ex situ and PCLS were 
prepared as previously described [5, 21, 22]. Briefly, the 
trachea was cannulated and the lungs were filled up with 
37  °C-warm, 1.5% low-gelling agarose medium solution 
(Sigma-Aldrich, Munich, Germany). After polymeriza-
tion of agarose to gel, lung lobes were cut into 200- to 
300-µm-thick slices using a Krumdieck microtome (Ala-
bama Research and Development, Munford, AL, USA) 
filled with 4 °C-cold EBSS (Sigma-Aldrich, Munich, Ger-
many). Subsequently, precision-cut lung slices were incu-
bated in DMEM (Dulbecco’s modified Eagle’s medium/
nutrient mixture F-12 Ham (DMEM, pH 7.2-7.4) with 
l-glutamine and 15  mM HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) without phenol red 
and fetal bovine serum supplied from Gibco™ (Life 
Technologies/Thermo Fisher Scientific, Dreieich, Ger-
many) supplemented with 100 units/mL penicillin and 
streptomycin (Lonza, Verviers, Belgium) under standard 
cell culture conditions (37  °C, 5% CO2, 100% humidity). 
Two PCLS were cultured together in 500 µL DMEM as 
described previously [21]. Different numbers of slices 
were pooled, as outlined in the RNA isolation section 
below, immediately transferred into liquid nitrogen and 
subsequently stored at −80 °C.
Isolation of cells from PCLS
After preparation each PCLS was placed in 200 µL diges-
tion solution (DMEM supplemented with 1% penicillin 
and streptomycin, 100  U/mL DNase I (Roche Diagnos-
tics, Mannheim, Germany), 2.4 U/mL Dispase® II (Roche 
Diagnostics, Mannheim, Germany), and 150  U/mL col-
lagenase 3 (Collagenase Worthington, Lakewood, USA)) 
and incubated for 30  min at 37  °C on an orbital shaker 
(650  rpm). Afterwards, slices were passed vigorously 
through a cut 1-mL tip and placed in a 100-µm CellTric® 
(Partec, Görlitz, Germany). Cells were rinsed with 600 µL 
ice-cold DMEM per slice, centrifuged for 3 min at 400×g 
at 4 °C, then immediately transferred into liquid nitrogen, 
and subsequently stored at −80 °C.
Cell culture
The human lung epithelial cell line A549 (ATCC® CCL-
185™) was obtained from ATCC (LGC Standards GmbH, 
Wesel, Germany). Cells were routinely cultured in 75-cm2 
flasks in Dulbecco’s modified Eagle’s medium (DMEM, 
Life Technologies/Thermo Fisher Scientific, Dreieich, 
Germany) supplemented with 10% fetal calf serum and 
0.01% gentamicin at 37  °C in a humidified atmosphere 
containing 5% CO2. Cell numbers used for RNA isolation 
are indicated in Figs.  2a and 3b. RNA from A549 cells 
was used in some experiments as a quality standard for 
comparison.
RNA isolation protocols
In a first step, four rat PCLS per tube were used for RNA 
isolation. Several commercially available kits were used for 
this according to the suppliers’ instructions: RNeasy Mini 
Kit (Qiagen, Hilden, Germany), QIAzol® (Qiagen, Hilden, 
Germany), MagJET (Thermo Fisher Scientific, Dreieich, 
Germany), and MagMAX™ (Ambion™/Thermo Fisher 
Scientific, Dreieich, Germany). Disruption and homogeni-
zation of PCLS in the respective solutions was performed 
using an Ultra-Turrax® (T8, IKA, Stauffen, Germany).
In a second step, optimized RNA extraction was 
achieved as follows: two PCLS were pooled, followed by 
disruption and homogenization of PCLS in 400 µL RLT 
lysis buffer (Qiagen, Hilden, Germany) using an Ultra-
Turrax®. The homogenate was transferred to 1 volume of 
phenol/chloroform, carefully shaken for 30 s, and centri-
fuged for 5 min at 12,000×g. Subsequently, 1 volume of 
chloroform/isoamyl alcohol was added, again carefully 
shaken for 30  s, and centrifuged for 5 min at 12,000×g. 
The aqueous phase was transferred and RNA was cleaned 
up with MagMAX™ magnetic beads including the spin 
procedure step according to the supplier’s instructions. 
Total RNA was dissolved in RNase-free water and stored 
at −80 °C. For some samples an additional clean up step 
was performed using the RNeasy Mini Kit clean up pro-
tocol (Qiagen, Hilden, Germany).
RNA from A459 cells was isolated with the commer-
cially available RNeasy Mini Kit according to the suppli-
er’s instructions.
RNA measurements, quality control and quality criteria
RNA concentration (A260) and purity (A260/A280 ratio) 
were measured by spectrophotometry (NanoDrop 1000 
Spectrophotometer, version 3.7, Thermo Fisher Sci-
entific, Dreieich, Germany). RNA integrity (RIN) was 
evaluated using an Agilent 2100 Bioanalyzer® (Agilent 
Technologies, Ratingen, Germany).
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Quantitative real time RT‑PCR analysis (RTqPCR)
Reverse transcription (RT) of RNA was performed using 
TATAA GrandScript cDNA Supermix (A103a/A103b, 
TATAA Biocenter, Gothenburg, Sweden). SYBR Green 
(TATAA SYBRGrandMaster Mix ROX (TA01-1875R, 
TATAA Biocenter, Gothenburg, Sweden) was used as a 
fluorescent dye to determine the amplified PCR products 
after each cycle. The following primer pairs were used: 
B2M (NM_004048.2), fwd: GAGGCTATCCAGCG-
TACTCCA, rev: CGGCAGGCATACTCATCTTTT, 
248  bp, (Invitrogen/Thermo Fisher Scientific, Dreieich, 
Germany); MUC5AC, #qHsaCID0017663, 144  bp (Bio-
Rad, Munich, Germany). qPCR conditions were as fol-
lows: 30 s 95 °C; 5 s 95 °C/30 s 60 °C, for 40 cycles; and 
15 s 95 °C/1 min 60 °C/30 s 95 °C for the melting curve. 
At the end of each extension phase, fluorescence was 
recorded and at the end of a run quantification cycles 
(Cq) were determined for each sample. Serial dilu-
tions of RT reactions (A549 for B2M, human PCLS for 
MUC5AC) were prepared in triplicate and samples were 
analyzed by qPCR to measure the Cq values. A plot 
of Cq values versus the logarithm of target concentra-
tions resulted in standard curves, which were used for 
efficiency calculations (10−(1/slope)  −  1, corresponding 
to 100%) [23–25]. To calculate the efficiency for several 
individual RNA samples, RNA was transcribed to cDNA 
(complementary DNA), two dilution steps within the log-
linear portion of the standard curve separated by factor 
10 were prepared (1:5, 1:50), and Cq values were meas-
ured. The Cq difference represents the slope, which was 
then used for efficiency calculation.
Transcriptome analysis
Microarray analysis was performed with Affymetrix 
GeneChip® Human Genome U133 Plus 2.0 Arrays, using 
250 ng RNA as input. All steps were performed accord-
ing to the manufacturer’s instructions for the Gene-
Chip® platform (3′IVT PLUS Reagent Kit, Affymetrix, 
Santa Clara, USA). The steps included first-strand cDNA 
synthesis, second-strand cDNA synthesis, synthesis of 
labeled cRNA by in  vitro transcription, purification of 
labeled cRNA, fragmentation, array hybridization, wash-
ing, staining, and final scanning of the arrays using the 
GeneChip® Scanner 3000 7G.
To examine the quality of the microarrays before and 
after normalization, we used the bioconductor package 
arrayQualityMetrics 3.24.0 [26] under R version 3.2.1 
together with R Studio [27]. For quality assessment two 
different automatically created HTML reports were inter-
preted. The results included between-array comparisons, 
array intensity distributions, variance mean dependence, 
and finally the individual array quality. Outlier detection 
considering the distances between array comparisons 
was performed by finding arrays for which the sum of the 
distances from all other arrays was exceptionally large. 
Outlier detection for the array intensity distributions was 
performed by computing the Kolmogorov–Smirnov sta-
tistic Ka between distributions of intensity values of all 
samples in each array and the distribution of the values 
in the pooled data. The threshold was determined to be 
0.0249. Regarding the individual array intensity, the mass 
of the distribution in an MA plot is expected to be con-
centrated along the M = 0 axis with no trend in M (log 
ratios) as a function of A (mean average). Outliers were 
detected by computing Hoeffding’s statistic Da on the 
joint distribution of A and M for each array. The normal-
ized data were imported into the geneXplain platform 
(www.genexplain-platform.com) to perform a principal 
component analysis (PCA). The geneXplain platform was 
further used to detect differentially expressed genes for 
all samples with the EBarrays workflow.
Results
Establishment of an optimized protocol for RNA isolation 
from PCLS from different species
For the starting experiments, we pooled four rat PCLS 
and used a column-based standard RNA isolation pro-
tocol (RNeasy Mini Kit). Unfortunately, this standard 
isolation procedure did not yield intact RNA (Table  1). 
We assumed that saturation of PCLS with agarose might 
interfere with RNA extraction using a column-based 
isolation procedure. To determine the amount of RNA 
to be expected, we isolated intact cells from fresh slices 
and subsequently isolated RNA using the column-based 
standard protocol. We obtained about 1 µg RNA of good 
quality with an A260/A280 ratio of around 2.0 and a RIN 
value above 7.0 (Table 1). Isolation of intact cells is feasi-
ble only from fresh slices; however, comfortable handling 
of RNA isolation in different experimental approaches 
requires initial storage of PCLS at −80  °C. Therefore, 
we tried several other commercial RNA isolation kits 
based on diverse procedures. Using the monophasic lysis 
reagent QIAzol, followed by precipitation and column 
purification, the resulting RNA did also not meet the 
quality criteria (Table 1). A different kind of RNA isola-
tion is achived by combining a monophasic lysis reagent 
with magnetic-bead purification. Using MagJET or Mag-
MAX™ beads and following the protocol according to 
the supplier’s instructions, only the MagMAX™ beads 
yielded good RNA quality, with an A260/A280 ratio of 
around 1.95 and a RIN value above 8.0 (Table 1).
To optimize RNA yield and quality we modified the 
MagMAX procedure by dividing the first step (monopha-
sic lysis reagent) into a separate lysis procedure followed 
by conventional phenol–chloroform–isoamyl alcohol 
extraction (see “Methods”/“RNA isolation protocols” 
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sections). This procedure allows a yield of at least 1 µg 
RNA to be isolated from two pooled PCLS from humans, 
rhesus monkeys, marmosets, rats, and mice (Table  2). 
RNA was of good quality, as evaluated by the A260/A280 
ratio (around 1.9) and by RIN values (around 8.0). Addi-
tionally, an incubation period of 3 days, which is com-
monly used in several experimental approaches with 
PCLS, had no negative impact on RNA quality (Table 2). 
An example of RNA quality assessment for human PCLS 
is shown in Fig. 1. 
Relationship between RNA yield and 260/230 absorbance
Quality parameters were evaluated in over 20 differ-
ent isolation experiments per species (human, marmo-
set, rat, mouse). For all samples tested, the A260/A280 
ratio and the RIN values met the requested criteria, 
with A260/A280 ratios  >1.8 and RIN values  >7 (Fig.  2a). 
A260/A230 ratio differed between samples. For human, 
marmoset, and rat PCLS an A260/A230 ratio much lower 
than 2.0 was measured, whereas for mouse PCLS as well 
as for different preparations of A549 cells used as qual-
ity standard the A260/A230 ratio was around 2.0 (Fig. 2a). 
With the same slice size mouse PCLS contain greater cell 
numbers per slice than other species. Therefore, RNA 
isolation from mouse PCLS resulted in a higher RNA 
concentration than with other species. The data indi-
cate that the A260/A230 ratio in the preparations strongly 
depends on the RNA concentration of the sample, as low 
RNA concentrations of <100 ng/µL resulted in A260/A230 
ratios  <2.0 (Fig.  2b). Introducing an additional clean-up 
step resulted in higher concentrations and improvement 
of the A260/A230 ratio to around 2.0 (Fig.  2c). However, 
this step further substantially reduced the already small 
RNA yield (Fig.  2c), and, therefore, restricted the num-
ber of possible downstream applications. As we prepared 
all samples according to the same protocol, we assumed 
that they would all contain the same amount of contami-
nants absorbing at A230 despite the different A260/A230 
ratios. In this case, the low ratio would solely depend on 
the concentration of RNA, while the amount of contami-
nants that would be transferred to downstream applica-
tions might not be different. PCR is extremely sensitive to 
impurities such as salts, phenol, chloroform, and EDTA, 
which is why we subsequently tested wether different 
Table 1 Comparison of commercially available RNA isolation kits for use with PCLS
Results represent the means of at least three samples
N/A not available
a N/A data were calculated as RIN zero (4 out of 6 samples)
Material Kit RNA yield (ng) Absorbance 
260/280
RIN
Avg. Min. Avg. Min. Avg. Min.
Freshly isolated cells from rat PCLS RNeasy Mini Kit, Qiagen 1146.5 855.0 2.04 1.99 7.8 7.4
Rat PCLS stored at −80 °C RNeasy Mini Kit, Qiagen <100 N/A N/A N/A N/A N/A
Rat PCLS stored at −80 °C QIAzol®, Qiagen 413.3 127.8 1.64 1.37 2.7a N/A
Rat PCLS stored at −80 °C MagJET, ThermoFisher 737.0 312.3 2.21 1.94 5.8 N/A
Rat PCLS stored at −80 °C MagMAX™, Ambion/ThermoFisher 1527.4 601.5 1.95 1.78 8.9 8.4
Table 2 RNA isolation from PCLS from different species using an optimized protocol
The average is indicated ± STABW. Student’s t-test was performed to compare absorbance 260/280 and RIN values with and without an incubation period, p-values 
are indicated
n indicates the number of analysed samples, w/o without
Species Incu‑bation period RNA yield (µg) Absorbance 260/280 RIN value
Mean Min. Mean Min. p value Mean Min. p value
Human (n = 12) w/o 1.12 ± 0.44 0.62 1.91 ± 0.07 1.79 8.9 ± 0.7 7.8
Human, donor 1 (n = 12) 3 days 2.34 ± 1.03 1.34 1.90 ± 0.04 1.81 0.9107 8.7 ± 0.3 8.1 0.2691
Human, donor 2 (n = 12) 3 days 1.52 ± 0.15 1.29 1.91 ± 0.09 1.75 0.4783 9.0 ± 0.4 8.6 0.7983
Human, donor 3 (n = 12) 3 days 0.98 ± 0.28 0.56 1.88 ± 0.11 1.77 0.9701 9.0 ± 0.5 8.4 0.8112
Rhesus (n = 5) w/o 2.02 ± 0.37 1.58 1.91 ± 0.06 1.87 8.2 ± 0.5 7.4
Marmoset (n = 5) w/o 1.37 ± 0.16 1.16 1.87 ± 0.07 1.79 8.2 ± 0.3 7.8
Rat (n = 5) w/o 3.80 ± 0.78 2.48 1.95 ± 0.04 1.91 8.3 ± 1.0 6.8
Mouse (n = 5) w/o 5.67 ± 0.61 4.65 1.95 ± 0.01 1.93 8.2 ± 0.5 7.3
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A260/A230 ratios of our samples would affect RTqPCR 
analysis.
RTqPCR as a follow‑up endpoint for RNA from human PCLS
Potential inhibition of PCR by contaminants can be 
evaluated by analyzing the effect on amplification effi-
ciency. Therefore, we established a standard curve with 
A549 RNA as a quality standard (A260/A280 = 2.09, A260/
A230 = 2.12, RIN = 9.3) for the reference gene B2M. Sev-
eral cDNA dilutions were used, starting with a cDNA 
equivalent to 50 ng RNA. The resulting calibration curve 
indicates an amplification efficiency of 95.1% for this spe-
cific A549 RNA preparation (Fig. 3a). For efficiency com-
parison, we tested RNA samples with low concentrations 
(below 50 ng/µL) and a low A260/A230 ratio and RNA sam-
ples with higher concentrations above 100 ng/µL and an 
A260/A230 ratio around 2.0, from human PCLS and A549 
cells, respectively (Fig.  3b). The results show that PCR 
amplification efficiency was around 95% for all samples, 
independent of the A260/A230 ratio (Fig.  3b). These data 
support the hypothesis, that the total amount of contam-
inants with absorbance at 230  nm that is transferred to 
the RTqPCR seems to be low and might be disregarded in 
our preparations. The low A260/A230 ratio is only a result 
of the low RNA concentration, so that further clean-up 
steps, improving the ratio but at the same time strongly 
reducing the total amount of RNA, are unnecessary. 
Finally, we analyzed the expression of an airway-specific 
gene. MUC5AC is one of the polymeric mucins forming 
the airway mucus gel under normal physiological con-
ditions, with overproduction in chronic airway diseases 
[28]. The standard curve is linear (r2 = 0.9936) and indi-
cates an amplification efficiency of 100.6%, the melting 
curve shows a single peak, and the gel image shows a sin-
gle band for each dilution (Fig. 3c). In summary, applying 
our optimized RNA extraction protocol, RNA prepara-
tions from PCLS are well suited for RTqPCR as a down-
stream analysis.
Genome‑wide gene expression analysis as a follow‑up 
endpoint for RNA from of human PCLS
Finally, we verified wether RNA isolated from PCLS sam-
ples can be used for microarray analysis. For this evalua-
tion, we used RNA from PCLS from three human donors 
3 days after treatment with different chemicals (1 control 
and 11 different treatments, n = 36 samples in total, A260/
A280 absorbance ratio = 1.90 ± 0.08, RIN = 8.9 ± 0.4).
Firstly, we evaluated wether low A260/A230 ratios of 
RNA from human PCLS affect the yield of cRNA using 
the 3′IVT PLUS Reagent Kit (Affymetrix, Santa Clara, 
USA). Here again, we used A549 RNA with an A260/A230 
ratio of 1.9 as a quality standard for comparison (Table 3). 
Due to low RNA concentrations (see above), the human 
PCLS RNA preparations have much lower A260/A230 
ratios (Table  3). In microarray experiments, 250  ng 
RNA resulted in the same yield of cRNA in all samples 
(Table 3). These results indicate that the RNA from PCLS 
contained no contaminants that might have interfered 
with any enzymatic step during the Affymetrix protocol.
Secondly, we performed quality assessment of the 
microarrays. Using the bioconductor package array-
QualityMetrics, we did not detect a high number of 
outlier arrays that might have been due to problems in 
the experimental procedure. Only two outliers (arrays 8 
and 31) were identified after background correction and 
normalization in the section about distances between 
array comparisons, drawn with a false color heatmap 
(data not shown). Figure 4a shows the array signal inten-
sity distributions of the RMA normalized data and rep-
resents summaries in box plots. The boxes of the signal 
intensity distribution box plot have similar positions and 
widths. Only array 8 shows a slide shift, indicating back-
ground signals. Figure  4b presents density histograms 
of the microarrays. The curves of the individual donors 
are superimposed. There was no reduction of the right 
tail, which would have indicated a lack of signals, nor a 
prominent bulge at the upper end of the intensity range, 
indicating signal saturation. Only array 8 shows a slide 
shift, indicating background signals. Figure  4c shows 
eight MA plots to figure out the individual array quality. 
Fig. 1 Assessment of RNA quality for human PCLS. Representative 
bioanalyzer results showing the quality of RNA isolated from 10 differ-
ent human PCLS samples (virtual RNA gel format and electrophero-
gram depicting fluorescence units versus run time in seconds)
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Concerning the individual array intensities we could 
not observe arrays with different background intensities 
(trend in the lower range of A) or a saturation of signals 
(trend in the upper range of A). PCA is used to project 
the multivariate data vector of all substance groups into 
a two-dimensional plot. Figure 4d shows a scatterplot of 
items of four different substance groups at their trans-
formed coordinates according to the first two princi-
pal components. No clustering of substance groups was 
observed during PCA, which is a good basis for further 
downstream analyses [29]. Due to the good RNA quality, 
we were able to detect differentially expressed genes for 
all samples.
Conclusion
The large amount of agarose in PCLS impedes RNA 
extraction, making it difficult to obtain RNA of high 
quality from lung tissue ex vivo. We used several stand-
ard procedures and finally established a protocol for 












Before Clean Up 95.6 ± 33.9 4.3 ± 1.5 1.93 ± 0.04 1.48 ± 0.14











A549 cells, 2x106 6 1239 ± 60 37.2 ± 1.8 9.2 ± 0.6 2.10 ± 0.01 2.10 ± 0.11
A549 cells, 1x106 3 688.8 ± 50.6 30.2 ± 9.8 8.9 ± 0.4 2.05 ± 0.03 2.02 ± 0.09
Mouse PCLS 28 133.2 ± 30.8 6.7 ± 1.5 7.8 ± 0.5 1.94 ± 0.02 1.82 ± 0.11
Human PCLS 62 49.6 ± 35.4 2.2 ± 1.6 9.0 ± 0.6 1.91 ± 0.07 0.89 ± 0.42
Marmoset PCLS 44 37.6 ±  9.1 1.7 ± 0.4 8.2 ± 1.1 1.82 ± 0.09 0.71 ± 0.32
Rat PCLS 28 35.1 ±  21.2 1.7 ± 1.1 8.6 ± 0.5 1.96 ± 0.09 1.16 ± 0.27
Fig. 2 Relationship between RNA yield and 260/230 absorbance. a Concentration, yield, RIN, and absorbance ratios of RNA from A459 cells and 
from PCLS from different species (two slices each). b Correlation between RNA concentration and absorbance ratio 260/230. c RNA yield and 
absorbance ratio prior to and after the clean up procedure. Results represent the means of ten human PCLS samples
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marmosets, and rhesus macaques. The method is based 
on the separation of lysis and precipitation steps, and 
an additional magnetic-bead clean-up procedure. The 
resulting RNA is of high purity, possesses a high degree 
of integrity, and is well suited for RTqPCR and microar-
ray analyses as downstream applications.
Abbreviations
Cq: quantification cycle; DMEM: Dulbecco’s Modified Eagle Medium; EBSS: 
Earle’s Balanced Salt Solution; PCA: principal component analysis; PCLS: 
precision-cut lung slices; RIN: RNA integrity number; rpm: rounds per minute; 























































Human PCLS > 100 1.90 ± 0.03 2.02 ± 0.31 95.6 ± 4.6
Human PCLS < 50 1.93 ± 0.05 1.02 ± 0.45 95.0 ± 4.1
A549 cells, 5x105 > 100 2.04 ± 0.04 2.01 ± 0.15 97.0 ± 7.2
A549 cells, 1x105 < 50 2.04 ± 0.08 1.14 ± 0.50 94.1 ± 5.0
Fig. 3 RTqPCR as a follow-up endpoint of RNA from human PCLS. a Efficiency calculation for B2M primer using several A549 cDNA dilutions. b 
Efficiency analysis for different RNA preparations from A549 cells and human PCLS (different donors). Results represent the means of at least three 
samples (RIN > 7.0). c MUC5AC expression in human PCLS as an example of lung-specific gene expression (calibration curve, melting curve, gel 
image)
Table 3 cRNA yield after  sample preparation with  3′ IVT 
PLUS Reagent Kit (Affymetrix)
250 ng RNA were used as starting material. Results represent the means of 20 
samples, all samples with A260/A280 ratios around 1.9 and RIN values above 8.0
Material Absorbance 260/230 Yield cRNA (µg)
A549 cells 1.90 ± 0.17 58.6 ± 15.6
Human PCLS 0.60 ± 0.21 51.5 ± 12.1
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of all groups for the first two principal components
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